



Tuesday 1 September 2009

**Allergy Therapeutics plc**  
("Allergy Therapeutics" or "the Company")

**Confirmation of Management Change**

Allergy Therapeutics (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, confirms that, further to the Company's announcement of 12 June 2009, Manuel Lobet has today assumed the role of Chief Executive Officer and becomes an Executive Director of the Company.

Keith Carter has today stepped down from the position of Chief Executive Officer and takes up a position on the board as a Non-Executive Director.

Ignace Goethals, Non-Executive Chairman of Allergy Therapeutics, said: *"I warmly welcome Manuel as our new CEO. Manuel has a wealth of experience in many pharmaceutical markets, geographical and therapeutic. His expertise, in particular with respect to sales and marketing, will be most valuable to the company as it continues to grow sales, market share and profitability. On behalf of the Board I would like to thank Keith for providing a smooth handover and for his multiple contributions to the Company over the full ten years of its existence. We look forward to working with Keith in his capacity as Non-Executive Director. His knowledge of the business and products will be invaluable as we seek to continue to grow the business."*

**For further information**

**Allergy Therapeutics**

Ian Postlethwaite, Finance Director  
[www.allergytherapeutics.com](http://www.allergytherapeutics.com)

+44 (0) 1903 845 820

**Nomura Code Securities**

Juliet Thompson/ Clare Terlouw

+44 (0) 207 776 1200

**Financial Dynamics**

Ben Brewerton/ Susan Quigley

+44 (0) 207 831 3113